A citation-based method for searching scientific literature

Vasudha Tandon, Laureano de la Vega, Sourav Banerjee. J Biol Chem 2021
Times Cited: 16







List of co-cited articles
62 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, Martín Garrido-Rodríguez, Rosario Morrugares, Eduardo Muñoz, Marco A Calzado. Cell Mol Life Sci 2020
14
50

The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Rita Moreno, Sourav Banerjee, Angus W Jackson, Jean Quinn, Gregg Baillie, Jack E Dixon, Albena T Dinkova-Kostova, Joanne Edwards, Laureano de la Vega. Cell Death Differ 2021
11
63

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Sourav Banerjee, Tiantian Wei, Jue Wang, Jenna J Lee, Haydee L Gutierrez, Owen Chapman, Sandra E Wiley, Joshua E Mayfield, Vasudha Tandon, Edwin F Juarez,[...]. Proc Natl Acad Sci U S A 2019
24
37

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Sourav Banerjee, Chenggong Ji, Joshua E Mayfield, Apollina Goel, Junyu Xiao, Jack E Dixon, Xing Guo. Proc Natl Acad Sci U S A 2018
70
37

The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.
Jacopo Boni, Carlota Rubio-Perez, Nuria López-Bigas, Cristina Fillat, Susana de la Luna. Cancers (Basel) 2020
27
31

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Xing Guo, Xiaorong Wang, Zhiping Wang, Sourav Banerjee, Jing Yang, Lan Huang, Jack E Dixon. Nat Cell Biol 2016
104
31


DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Rei Mimoto, Naoe Taira, Hiroyuki Takahashi, Tomoko Yamaguchi, Masataka Okabe, Ken Uchida, Yoshio Miki, Kiyotsugu Yoshida. Cancer Lett 2013
53
25

DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage.
Naoe Taira, Keishi Nihira, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. Mol Cell 2007
210
25

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Naoe Taira, Rei Mimoto, Morito Kurata, Tomoko Yamaguchi, Masanobu Kitagawa, Yoshio Miki, Kiyotsugu Yoshida. J Clin Invest 2012
94
25

Multiple functions of DYRK2 in cancer and tissue development.
Saishu Yoshida, Kiyotsugu Yoshida. FEBS Lett 2019
20
18

Regulation of Glioma Cells Migration by DYRK2.
Yifen Shen, Li Zhang, Donglin Wang, Yifeng Bao, Chao Liu, Zhiwei Xu, Wei Huang, Chun Cheng. Neurochem Res 2017
10
30

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Meera Soundararajan, Annette K Roos, Pavel Savitsky, Panagis Filippakopoulos, Arminja N Kettenbach, Jesper V Olsen, Scott A Gerber, Jeyanthy Eswaran, Stefan Knapp, Jonathan M Elkins. Structure 2013
97
18

ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage.
Naoe Taira, Hiroyuki Yamamoto, Tomoko Yamaguchi, Yoshio Miki, Kiyotsugu Yoshida. J Biol Chem 2010
51
18

Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs.
Pamela A Lochhead, Gary Sibbet, Nick Morrice, Vaughn Cleghon. Cell 2005
214
18

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Noriko Yamaguchi, Rei Mimoto, Nozomu Yanaihara, Yoshimi Imawari, Shinichi Hirooka, Aikou Okamoto, Kiyotsugu Yoshida. Tumour Biol 2015
28
18

The protein kinase complement of the human genome.
G Manning, D B Whyte, R Martinez, T Hunter, S Sudarsanam. Science 2002
18

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.
Steven E Guard, Zachary C Poss, Christopher C Ebmeier, Maria Pagratis, Helen Simpson, Dylan J Taatjes, William M Old. Sci Rep 2019
19
12

DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Chun Shik Park, H Daniel Lacorazza. Exp Mol Med 2020
3
66

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Rahul S Bhansali, Malini Rammohan, Paul Lee, Anouchka P Laurent, Qiang Wen, Praveen Suraneni, Bon Ham Yip, Yi-Chien Tsai, Silvia Jenni, Beat Bornhauser,[...]. J Clin Invest 2021
18
12

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
Apirat Chaikuad, Julien Diharce, Martin Schröder, Alicia Foucourt, Bertrand Leblond, Anne-Sophie Casagrande, Laurent Désiré, Pascal Bonnet, Stefan Knapp, Thierry Besson. J Med Chem 2016
28
12

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Ramzi Abbassi, Terrance G Johns, Michael Kassiou, Lenka Munoz. Pharmacol Ther 2015
96
12

The protein interaction landscape of the human CMGC kinase group.
Markku Varjosalo, Salla Keskitalo, Audrey Van Drogen, Helka Nurkkala, Anton Vichalkovski, Ruedi Aebersold, Matthias Gstaiger. Cell Rep 2013
132
12

Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal morphogenesis.
Youngsik Woo, Soo Jeong Kim, Bo Kyoung Suh, Yongdo Kwak, Hyun-Jin Jung, Truong Thi My Nhung, Dong Jin Mun, Ji-Ho Hong, Su-Jin Noh, Seunghyun Kim,[...]. Elife 2019
17
12

Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
Kyeongmin Kim, Sungmin Lee, Hyunkoo Kang, Eunguk Shin, Hae Yu Kim, HyeSook Youn, BuHyun Youn. Int J Mol Sci 2021
5
40

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Amina Jamal Laham, Maha Saber-Ayad, Raafat El-Awady. Cell Mol Life Sci 2021
19
12

Crystal Structure of Human Dual-Specificity Tyrosine-Regulated Kinase 3 Reveals New Structural Features and Insights into its Auto-phosphorylation.
Kuglae Kim, Jeong Seok Cha, Yong-Soon Cho, Hoyoung Kim, Nienping Chang, Hye-Jung Kim, Hyun-Soo Cho. J Mol Biol 2018
9
22

Characterization of a domain that transiently converts class 2 DYRKs into intramolecular tyrosine kinases.
Ross Kinstrie, Nathan Luebbering, Diego Miranda-Saavedra, Gary Sibbet, Jingfen Han, Pamela A Lochhead, Vaughn Cleghon. Sci Signal 2010
31
12


FDA-approved small-molecule kinase inhibitors.
Peng Wu, Thomas E Nielsen, Mads H Clausen. Trends Pharmacol Sci 2015
593
12

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Jeroni Luna, Jacopo Boni, Miriam Cuatrecasas, Xavier Bofill-De Ros, Estela Núñez-Manchón, Meritxell Gironella, Eva C Vaquero, Maria L Arbones, Susana de la Luna, Cristina Fillat. Gut 2019
35
12


The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2.
Florian Glenewinkel, Michael J Cohen, Cason R King, Sophie Kaspar, Simone Bamberg-Lemper, Joe S Mymryk, Walter Becker. Sci Rep 2016
26
12

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.
Hua Chen, Jacson Shen, Edwin Choy, Francis J Hornicek, Aijun Shan, Zhenfeng Duan. Oncotarget 2017
10
20

DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Olga Bogacheva, Oleg Bogachev, Madhu Menon, Arvind Dev, Estelle Houde, Elizabeth I Valoret, Haydn M Prosser, Caretha L Creasy, Susan J Pickering, Evelyn Grau,[...]. J Biol Chem 2008
21
12

Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Yingying Chen, Shuo Wang, Zhixian He, Fulan Sun, Yeqing Huang, Qichao Ni, Hua Wang, Yingying Wang, Chun Cheng. Hum Pathol 2017
13
15

Kinase-controlled phase transition of membraneless organelles in mitosis.
Arpan Kumar Rai, Jia-Xuan Chen, Matthias Selbach, Lucas Pelkmans. Nature 2018
172
12

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
Tomotaka Kumamoto, Kohji Yamada, Saishu Yoshida, Katsuhiko Aoki, Shinichi Hirooka, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Int J Oncol 2020
10
20

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Tania Tahtouh, Jonathan M Elkins, Panagis Filippakopoulos, Meera Soundararajan, Guillaume Burgy, Emilie Durieu, Claude Cochet, Ralf S Schmid, Donald C Lo, Florent Delhommel,[...]. J Med Chem 2012
138
12

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Natividad Pozo, Cristina Zahonero, Paloma Fernández, Jose M Liñares, Angel Ayuso, Masatoshi Hagiwara, Angel Pérez, Jose R Ricoy, Aurelio Hernández-Laín, Juan M Sepúlveda,[...]. J Clin Invest 2013
86
12

Dyrk kinases regulate phosphorylation of doublecortin, cytoskeletal organization, and neuronal morphology.
Tatiana I Slepak, Lindsey D Salay, Vance P Lemmon, John L Bixby. Cytoskeleton (Hoboken) 2012
23
12

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Shiho Yokoyama-Mashima, Satomi Yogosawa, Yumi Kanegae, Shinichi Hirooka, Saishu Yoshida, Takashi Horiuchi, Toya Ohashi, Katsuhiko Yanaga, Masayuki Saruta, Tsunekazu Oikawa,[...]. Cancer Lett 2019
16
12

Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling.
Frank Wippich, Bernd Bodenmiller, Maria Gustafsson Trajkovska, Stefanie Wanka, Ruedi Aebersold, Lucas Pelkmans. Cell 2013
359
12

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Haiyan Yan, Kaishun Hu, Wenjing Wu, Yu Li, Huan Tian, Zhonghua Chu, H Phillip Koeffler, Dong Yin. PLoS One 2016
20
12

Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Rei Mimoto, Naoe T Nihira, Shinichi Hirooka, Hiroshi Takeyama, Kiyotsugu Yoshida. Cancer Lett 2017
13
15

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
R Mimoto, Y Imawari, S Hirooka, H Takeyama, K Yoshida. Oncogene 2017
22
12

COSMIC: the Catalogue Of Somatic Mutations In Cancer.
John G Tate, Sally Bamford, Harry C Jubb, Zbyslaw Sondka, David M Beare, Nidhi Bindal, Harry Boutselakis, Charlotte G Cole, Celestino Creatore, Elisabeth Dawson,[...]. Nucleic Acids Res 2019
12

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.
Yousang Gwack, Sonia Sharma, Julie Nardone, Bogdan Tanasa, Alina Iuga, Sonal Srikanth, Heidi Okamura, Diana Bolton, Stefan Feske, Patrick G Hogan,[...]. Nature 2006
288
12

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Yasuko Enomoto, Shin-ichi Yamashita, Yasuteru Yoshinaga, Yasuyoshi Fukami, So Miyahara, Kazuki Nabeshima, Akinori Iwasaki. Tumour Biol 2014
23
12

Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Daisuke Ito, Satomi Yogosawa, Rei Mimoto, Shinichi Hirooka, Takashi Horiuchi, Ken Eto, Katsuhiko Yanaga, Kiyotsugu Yoshida. Cancer Sci 2017
20
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.